Effect of, OAT3, on the Renal Secretion of Cefotaxime

Phase 1 Completed 24 enrolled University of California, San Francisco

NaSingle-groupOpen-labelHealth-services research

Summary

In the proposed study, we plan to use a genotype to phenotype strategy to study the role of the organic anion transporter, OAT3, in drug response. More specifically we will examine the contribution of OAT3 to the renal clearance of anionic drugs such as cefotaxime by studying individuals with a non-functional (or poorly-functional) variant of OAT3.

Timeline

Start: 2004-01
Primary completion: 2011-12
Completion: 2013-12

Publications

Results Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Giacomini KM. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol. 2006 Apr;290(4):F905-12. doi: 10.1152/ajprenal.00272.2005. Epub 2005 Nov 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cefotaxime	Small molecule	2 g	Intravenous

Indications

No indication recorded.